Arrowhead Pharmaceuticals (ARWR) Other Non-Current Assets (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 17 years of Other Non-Current Assets data on file, last reported at $4.9 million in Q1 2026.

• Quarterly Other Non-Current Assets rose 272.48% year-over-year to $4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 million (up 272.48% YoY) and the FY2025 annual result came in at $1.4 million, down 69.01% from the prior year.
• Other Non-Current Assets grew to $4.9 million in Q1 2026, from $1.4 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $4.9 million in Q1 2026 to a low of $210000.0 in Q4 2022.
• A 5-year average of $1.6 million and a median of $1.3 million in 2025 frame the typical range for Other Non-Current Assets.
• Annual changes were most pronounced in 2024 — Other Non-Current Assets jumped 2023.81% — and 2025, when it plunged 69.66%.
• Tracing ARWR's Other Non-Current Assets over 5 years: stood at $210000.0 in 2022, then gained by 10.48% to $232000.0 in 2023, then soared by 1228.88% to $3.1 million in 2024, then sank by 54.23% to $1.4 million in 2025, then jumped by 246.35% to $4.9 million in 2026.
• The last three Other Non-Current Assets figures came in at $4.9 million (Q1 2026), $1.4 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.